TABLE 3.
Number and proportion of dogs with clinical cure at 3‐4 weeks and median duration of treatment depending on studied criteria
| Cured at 3–4 weeks | P values (Chi test) | Median duration | P values (Mann Whitney test) | |
|---|---|---|---|---|
| Less than 6‐month‐old n = 31 | 13/31 (42%) | .16 | 5 | .65 |
| More than 6‐month‐old n = 14 | 9/14 (64%) | 4 | ||
| Brachycephalic dogs n = 13 | 5/13 (38%) | .37 | 5 | .79 |
| Non brachycephalic dogs n = 32 | 17/32 (53%) | 4 | ||
| Dogs with cough <2 weeks n = 6 | 3/6 (50%) | 1.00 | 4 | .68 |
| Dogs with cough >2 weeks n = 40 | 19/40 (48%) | 5 | ||
| Co‐infection with other bacteria n = 4 | 3/4 (75%) | .27 | 4 | .71 |
| No co‐infection with other bacteria n = 41 | 19/41 (46%) | 5 | ||
| Co‐infection with M. cynos n = 18 | 8/18 (44%) | .92 | 5 | .88 |
| No co‐infection with M. cynos n = 13 | 6/13 (46%) | 5 | ||
| Radiographic alveolar lesions n = 25 | 11/25 (44%) | .46 | 5 | .44 |
| No radiographic alveolar lesions n = 20 | 11/20 (55%) | 4 | ||
| Previous steroid treatment n = 12 | 6/12 (50%) | .93 | 4.5 | .87 |
| No previous steroid treatment n = 34 | 16/33 (48%) | 5 | ||
| TCC of BALF >1000 cells/μL n = 25 | 10/25 (40%) | .04 | 6 | .08 |
| TCC of BALF <1000 cells/μL n = 15 | 11/15 (73%) | 4 | ||
| % neutrophils on BALF >50% n = 25 | 12/25 (48%) | .46 | 5 | .53 |
| % neutrophils on BALF <50% n = 15 | 9/15 (60%) | 4 | ||
| Concomitant oral antimicrobial treatment a n = 21 | 9/21 (43%) | .36 | 5 | .49 |
| No concomitant oral antimicrobial treatment n = 23 | 13/23 (57%) | 4 | ||
| Use of transport cage n = 31 | 15/31 (48%) | 1.00 | 5 | .35 |
| Use of facial mask n = 15 | 7/15 (47%) | 4.5 | ||
| Airways abnormalities n = 5 | 2/5 (40%) | .67 | 5 | .57 |
| No airways abnormalities n = 40 | 20/40 (50%) | 4.5 | ||
| Protocol 1 n = 13 | 3/13 (23%) | .03 | 6, range 3–8 [interquartile: 4.7‐6] | .01 |
| Protocol 2 n = 33 | 19/33 (58%) | 4 range 3–6 [interquartile: 3‐4] |
Note: Brachycephalic dogs included Boxer and French and English Bulldog. Airways abnormalities including tracheal or bronchial collapse and epiglottic retroversion. Protocol 1: fixed dose of 4 mg/kg of gentamicin with dilution in saline; Protocol 2: fixed undiluted concentration of 5% of gentamicin solution. Significance values are given in bold.
Abbreviations: BALF: bronchoalveolar lavage fluid; M. cynos: Mycoplasma cynos; qPCR, quantitative polymerase chain reaction; TCC, total cell count of bronchoalveolar lavage.
a
Amoxicillin/clavulanic acid, doxycycline, or enrofloxacin.